Co-Authors
This is a "connection" page, showing publications co-authored by RADHE MOHAN and STEVEN HSESHENG LIN.
Connection Strength
4.868
-
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
Score: 0.714
-
Personalized Composite Dosimetric Score-Based Machine Learning Model of Severe Radiation-Induced Lymphopenia Among Patients With Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2024 Nov 15; 120(4):1172-1180.
Score: 0.239
-
Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer. Int J Part Ther. 2024 Mar; 11:100012.
Score: 0.237
-
Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):368-377.
Score: 0.227
-
Predicting Severity of Radiation Induced Lymphopenia in Individual Proton Therapy Patients for Varying Dose Rate and Fractionation Using Dynamic 4-Dimensional Blood Flow Simulations. Int J Radiat Oncol Biol Phys. 2023 Aug 01; 116(5):1226-1233.
Score: 0.218
-
RE: Venkatesulu et al. (Letter to the Editor). Radiother Oncol. 2023 04; 181:109490.
Score: 0.218
-
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100391.
Score: 0.211
-
Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation Therapy. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100959.
Score: 0.206
-
Design and validation of a synchrotron proton beam line for FLASH radiotherapy preclinical research experiments. Med Phys. 2022 Jan; 49(1):497-509.
Score: 0.201
-
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021 02 25; 23(2):284-294.
Score: 0.191
-
The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol. 2020 05; 146:180-186.
Score: 0.179
-
A novel deep learning model using dosimetric and clinical information for grade 4 radiotherapy-induced lymphopenia prediction. Phys Med Biol. 2020 02 04; 65(3):035014.
Score: 0.177
-
Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. Pract Radiat Oncol. 2020 Jan - Feb; 10(1):e16-e26.
Score: 0.171
-
The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiother Oncol. 2019 04; 133:9-15.
Score: 0.165
-
High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol. 2018 09; 128(3):584-590.
Score: 0.155
-
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
Score: 0.153
-
Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol. 2013 Dec; 8(12):1484-91.
Score: 0.116
-
Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
Score: 0.103
-
Defining the Optimal Radiation-induced Lymphopenia Metric to Discern Its Survival Impact in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2025 Jan 02.
Score: 0.062
-
Discordance in acute gastrointestinal toxicity between synchrotron-based proton and linac-based electron ultra-high dose rate irradiation. bioRxiv. 2024 Sep 08.
Score: 0.061
-
Clinical Translation of a Deep Learning Model of Radiation-Induced Lymphopenia for Esophageal Cancer. Int J Part Ther. 2024 Sep; 13:100624.
Score: 0.061
-
Radiation-Induced Lymphopenia is a Causal Mediator of Survival After Chemoradiation Therapy for Esophagus Cancer. Adv Radiat Oncol. 2024 Oct; 9(10):101579.
Score: 0.060
-
Declarations of Independence: How Embedded Multicollinearity Errors Affect Dosimetric and Other Complex Analyses in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1054-1062.
Score: 0.056
-
Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions. Neoplasia. 2023 05; 39:100889.
Score: 0.055
-
Adaptation and dosimetric commissioning of a synchrotron-based proton beamline for FLASH experiments. Phys Med Biol. 2022 08 05; 67(16).
Score: 0.053
-
A hybrid deep learning model for forecasting lymphocyte depletion during radiation therapy. Med Phys. 2022 May; 49(5):3507-3522.
Score: 0.051
-
Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. JCO Clin Cancer Inform. 2021 09; 5:1044-1053.
Score: 0.049
-
Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. Radiother Oncol. 2021 10; 163:192-198.
Score: 0.049
-
Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys. 2021 11 15; 111(4):907-916.
Score: 0.049
-
Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients. Int J Part Ther. 2021; 8(2):17-27.
Score: 0.048
-
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69.
Score: 0.048
-
Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol. 2021 01; 154:187-193.
Score: 0.046
-
Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. Adv Radiat Oncol. 2021 Jan-Feb; 6(1):100545.
Score: 0.046
-
Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563.
Score: 0.039
-
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
Score: 0.037
-
Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
Score: 0.034
-
Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. Sci Rep. 2015 May 18; 5:9850.
Score: 0.032
-
HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):e229-35.
Score: 0.026
-
Quantifying the interfractional displacement of the gastroesophageal junction during radiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e273-80.
Score: 0.026